Scott N VanderWel

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
    Scott N VanderWel
    Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2371-87. 2005
  2. ncbi Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Peter L Toogood
    Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2388-406. 2005

Detail Information

Publications2

  1. ncbi Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
    Scott N VanderWel
    Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2371-87. 2005
    ..The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice...
  2. ncbi Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Peter L Toogood
    Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2388-406. 2005
    ..On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer...